Immunome (NASDAQ:IMNM) Director Isaac Barchas Sells 16,906 Shares of Stock

Immunome, Inc. (NASDAQ:IMNM) Director Isaac Barchas sold 16,906 shares of Immunome stock in a transaction on Tuesday, July 7th. The stock was sold at an average price of $24.20, for a total transaction of $409,125.20. Following the completion of the sale, the director owned 108,504 shares of the company’s stock, valued at approximately $2,625,796.80. This trade represents a 13.48% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Isaac Barchas also recently made the following trade(s):

• On Monday, July 6th, Isaac Barchas sold 83,094 shares of Immunome stock. The stock was sold at an average price of $24.11, for a total value of $2,003,396.34.
• On Thursday, July 2nd, Isaac Barchas sold 100,000 shares of Immunome stock. The stock was sold at an average price of $22.59, for a total transaction of $2,259,000.00.
• On Tuesday, June 30th, Isaac Barchas sold 101,050 shares of Immunome stock. The shares were sold at an average price of $21.12, for a total transaction of $2,134,176.00.

Immunome Trading Up 2.1%

NASDAQ IMNM traded up $0.49 during trading hours on Tuesday, reaching $24.39. The company’s stock had a trading volume of 1,561,508 shares, compared to its average volume of 1,722,826. The business has a 50-day simple moving average of $20.99 and a 200 day simple moving average of $21.83. Immunome, Inc. has a 52 week low of $7.96 and a 52 week high of $27.65. The stock has a market cap of $2.76 billion, a PE ratio of -10.25 and a beta of 2.07.

Immunome (NASDAQ:IMNM) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($0.48) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.12. As a group, equities analysts predict that Immunome, Inc. will post -2.06 EPS for the current year.

Institutional Investors Weigh In On Immunome

Several institutional investors have recently bought and sold shares of IMNM. KBC Group NV bought a new stake in shares of Immunome during the 1st quarter worth about $60,000. BNP Paribas Financial Markets raised its holdings in Immunome by 81.8% during the second quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock worth $60,000 after purchasing an additional 2,909 shares in the last quarter. Strs Ohio bought a new stake in Immunome during the fourth quarter worth approximately $64,000. Tower Research Capital LLC TRC lifted its position in Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after purchasing an additional 3,802 shares during the period. Finally, Russell Investments Group Ltd. bought a new position in Immunome during the 3rd quarter valued at $76,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Analyst Upgrades and Downgrades

IMNM has been the subject of several recent research reports. Truist Financial upped their price target on shares of Immunome from $36.00 to $37.00 and gave the stock a “buy” rating in a research report on Thursday, May 28th. Barclays started coverage on shares of Immunome in a research note on Thursday, May 28th. They set an “overweight” rating and a $36.00 target price for the company. HC Wainwright restated a “buy” rating and issued a $40.00 target price on shares of Immunome in a research report on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Immunome in a report on Tuesday, April 21st. Finally, Wall Street Zen downgraded Immunome from a “hold” rating to a “sell” rating in a research report on Saturday, May 30th. Twelve research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $33.17.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.